Here at STAT, we’ve spent years following Alzheimer’s disease research and providing readers with extensive coverage of significant drug developments and frustrating failures. Back in August, we outlined everything you need to know before the next big Alzheimer’s readout. The outcome of this clinical trial is vitally important for millions of patients awaiting a medicine that can impact the disease — success could indicate a meaningful place to start after more than a decade of disappointing results.
You can find comprehensive coverage of the upcoming readout on STAT+, our premium subscription service. On this World Alzheimer’s Day, get 30% off an annual subscription and stay up-to-date on Alzheimer's disease and treatment. subscribe now Thank you for reading STAT. We’re especially grateful to our subscribers to STAT+, whose support gives us the resources to cover these important stories. Sincerely,  Adam Feuerstein + Damian Garde | 
No comments